Tenaya Therapeutics Statistics
Total Valuation
TNYA has a market cap or net worth of $132.30 million. The enterprise value is $67.37 million.
Important Dates
The last earnings date was Wednesday, November 6, 2024, after market close.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TNYA has 79.22 million shares outstanding. The number of shares has increased by 18.54% in one year.
| Current Share Class | 79.22M |
| Shares Outstanding | 79.22M |
| Shares Change (YoY) | +18.54% |
| Shares Change (QoQ) | +0.53% |
| Owned by Insiders (%) | 1.18% |
| Owned by Institutions (%) | 44.01% |
| Float | 55.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.17 |
| P/TBV Ratio | 1.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.27, with a Debt / Equity ratio of 0.13.
| Current Ratio | 5.27 |
| Quick Ratio | 4.91 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -84.49% and return on invested capital (ROIC) is -50.46%.
| Return on Equity (ROE) | -84.49% |
| Return on Assets (ROA) | -45.94% |
| Return on Capital (ROIC) | -50.46% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$837,343 |
| Employee Count | 140 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.25% in the last 52 weeks. The beta is 2.73, so TNYA's price volatility has been higher than the market average.
| Beta (5Y) | 2.73 |
| 52-Week Price Change | -34.25% |
| 50-Day Moving Average | 2.40 |
| 200-Day Moving Average | 3.26 |
| Relative Strength Index (RSI) | 37.59 |
| Average Volume (20 Days) | 7,494,363 |
Short Selling Information
The latest short interest is 14.05 million, so 17.73% of the outstanding shares have been sold short.
| Short Interest | 14.05M |
| Short Previous Month | 13.12M |
| Short % of Shares Out | 17.73% |
| Short % of Float | 25.47% |
| Short Ratio (days to cover) | 2.31 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -122.74M |
| Pretax Income | -120.74M |
| Net Income | -117.23M |
| EBITDA | -114.18M |
| EBIT | -122.74M |
| Earnings Per Share (EPS) | -$1.44 |
Full Income StatementBalance Sheet
The company has $79.47 million in cash and $14.54 million in debt, giving a net cash position of $64.93 million or $0.82 per share.
| Cash & Cash Equivalents | 79.47M |
| Total Debt | 14.54M |
| Net Cash | 64.93M |
| Net Cash Per Share | $0.82 |
| Equity (Book Value) | 112.60M |
| Book Value Per Share | 1.42 |
| Working Capital | 69.15M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$94.04 million and capital expenditures -$1.22 million, giving a free cash flow of -$95.25 million.
| Operating Cash Flow | -94.04M |
| Capital Expenditures | -1.22M |
| Free Cash Flow | -95.25M |
| FCF Per Share | -$1.20 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |